Related Experiment Video
Updated: May 21, 2026
08:06
Neonatal Subventricular Zone Electroporation
Published on: February 11, 2013
Neonatal neuroblastoma
Jonathan P H Fisher1, Deborah A Tweddle2
1Department of Paediatric Oncology, Great North Children's Hospital, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK.
Seminars in Fetal & Neonatal Medicine
|June 8, 2012
Summary
Neuroblastoma is the most common neonatal cancer. Many cases, especially metastatic (Ms) disease without adverse genetics, can be safely observed for spontaneous regression, avoiding unnecessary treatment.
Area of Science:
- Oncology
- Pediatric Oncology
- Neonatal Medicine
Background:
- Neuroblastoma is the most common neonatal malignancy, originating from the sympathetic nervous system.
- Presentation varies from antenatal adrenal masses to localized or metastatic (4s/Ms) disease.
- A subset of neonatal neuroblastoma (~20%) presents with spinal cord compression, necessitating urgent intervention.
Purpose of the Study:
- To review the management and outcomes of neonatal neuroblastoma.
- To identify patient subgroups suitable for observation versus active treatment.
- To evaluate the role of targeted screening for hereditary neuroblastoma.
Main Methods:
- Review of clinical presentation, risk stratification, and treatment outcomes for neonatal neuroblastoma.
- Analysis of genetic features (e.g., MYCN amplification, chromosomal abnormalities) and their impact on prognosis.
- Assessment of the efficacy of observation for low-risk metastatic (Ms) disease.
Main Results:
- Localized and stage Ms neonatal neuroblastoma without adverse genetic features often have favorable outcomes and may regress spontaneously.
- Spinal cord compression requires prompt treatment with steroids and chemotherapy.
- Targeted screening for infants with germline ALK or PHOX2B mutations is recommended for hereditary neuroblastoma.
Conclusions:
- Observation is a safe and effective strategy for select neonatal neuroblastoma patients, particularly those with stage Ms disease and no adverse genetic markers.
- Universal mass screening is not recommended, but targeted screening for high-risk infants is appropriate.
- Future research should focus on further refining criteria for observation in patients lacking adverse genetic or life-threatening features.
